Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study.

O'Bryant SE, Edwards M, Zhang F, Johnson LA, Hall J, Kuras Y, Scherzer CR.

Alzheimers Dement (Amst). 2019 May 2;11:374-382. doi: 10.1016/j.dadm.2019.03.001. eCollection 2019 Dec.

2.

DNA methylation changes associated with Parkinson's disease progression: outcomes from the first longitudinal genome-wide methylation analysis in blood.

Henderson-Smith A, Fisch KM, Hua J, Liu G, Ricciardelli E, Jepsen K, Huentelman M, Stalberg G, Edland SD, Scherzer CR, Dunckley T, Desplats P.

Epigenetics. 2019 Apr;14(4):365-382. doi: 10.1080/15592294.2019.1588682. Epub 2019 Mar 14.

PMID:
30871403
3.

Publisher Correction: Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease.

Dong X, Liao Z, Gritsch D, Hadzhiev Y, Bai Y, Locascio JJ, Guennewig B, Liu G, Blauwendraat C, Wang T, Adler CH, Hedreen JC, Faull RLM, Frosch MP, Nelson PT, Rizzu P, Cooper AA, Heutink P, Beach TG, Mattick JS, Müller F, Scherzer CR.

Nat Neurosci. 2019 Jan;22(1):144-147. doi: 10.1038/s41593-018-0277-z.

PMID:
30482917
4.

Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease.

Dong X, Liao Z, Gritsch D, Hadzhiev Y, Bai Y, Locascio JJ, Guennewig B, Liu G, Blauwendraat C, Wang T, Adler CH, Hedreen JC, Faull RLM, Frosch MP, Nelson PT, Rizzu P, Cooper AA, Heutink P, Beach TG, Mattick JS, Müller F, Scherzer CR.

Nat Neurosci. 2018 Oct;21(10):1482-1492. doi: 10.1038/s41593-018-0223-0. Epub 2018 Sep 17. Erratum in: Nat Neurosci. 2019 Jan;22(1):144-147.

5.

Finding useful biomarkers for Parkinson's disease.

Chen-Plotkin AS, Albin R, Alcalay R, Babcock D, Bajaj V, Bowman D, Buko A, Cedarbaum J, Chelsky D, Cookson MR, Dawson TM, Dewey R, Foroud T, Frasier M, German D, Gwinn K, Huang X, Kopil C, Kremer T, Lasch S, Marek K, Marto JA, Merchant K, Mollenhauer B, Naito A, Potashkin J, Reimer A, Rosenthal LS, Saunders-Pullman R, Scherzer CR, Sherer T, Singleton A, Sutherland M, Thiele I, van der Brug M, Van Keuren-Jensen K, Vaillancourt D, Walt D, West A, Zhang J.

Sci Transl Med. 2018 Aug 15;10(454). pii: eaam6003. doi: 10.1126/scitranslmed.aam6003. Review.

PMID:
30111645
6.

Discovering New Benefits From Old Drugs With Big Data-Promise for Parkinson Disease.

Olsen AL, Riise T, Scherzer CR.

JAMA Neurol. 2018 Aug 1;75(8):917-920. doi: 10.1001/jamaneurol.2018.0345. No abstract available.

PMID:
29710184
7.

β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease.

Mittal S, Bjørnevik K, Im DS, Flierl A, Dong X, Locascio JJ, Abo KM, Long E, Jin M, Xu B, Xiang YK, Rochet JC, Engeland A, Rizzu P, Heutink P, Bartels T, Selkoe DJ, Caldarone BJ, Glicksman MA, Khurana V, Schüle B, Park DS, Riise T, Scherzer CR.

Science. 2017 Sep 1;357(6354):891-898. doi: 10.1126/science.aaf3934.

8.

Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.

Gwinn K, David KK, Swanson-Fischer C, Albin R, Hillaire-Clarke CS, Sieber BA, Lungu C, Bowman FD, Alcalay RN, Babcock D, Dawson TM, Dewey RB Jr, Foroud T, German D, Huang X, Petyuk V, Potashkin JA, Saunders-Pullman R, Sutherland M, Walt DR, West AB, Zhang J, Chen-Plotkin A, Scherzer CR, Vaillancourt DE, Rosenthal LS.

Biomark Med. 2017 May;11(6):451-473. doi: 10.2217/bmm-2016-0370. Epub 2017 Jun 23.

9.

Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.

Liu G, Locascio JJ, Corvol JC, Boot B, Liao Z, Page K, Franco D, Burke K, Jansen IE, Trisini-Lipsanopoulos A, Winder-Rhodes S, Tanner CM, Lang AE, Eberly S, Elbaz A, Brice A, Mangone G, Ravina B, Shoulson I, Cormier-Dequaire F, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Marinus J, Scherzer CR; HBS; CamPaIGN; PICNICS; PROPARK; PSG; DIGPD; PDBP.

Lancet Neurol. 2017 Aug;16(8):620-629. doi: 10.1016/S1474-4422(17)30122-9. Epub 2017 Jun 16. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

10.

Defining the contribution of neuroinflammation to Parkinson's disease in humanized immune system mice.

Manocha GD, Floden AM, Puig KL, Nagamoto-Combs K, Scherzer CR, Combs CK.

Mol Neurodegener. 2017 Feb 14;12(1):17. doi: 10.1186/s13024-017-0158-z.

11.

Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's.

Liu G, Boot B, Locascio JJ, Jansen IE, Winder-Rhodes S, Eberly S, Elbaz A, Brice A, Ravina B, van Hilten JJ, Cormier-Dequaire F, Corvol JC, Barker RA, Heutink P, Marinus J, Williams-Gray CH, Scherzer CR; International Genetics of Parkinson Disease Progression (IGPP) Consortium.

Ann Neurol. 2016 Nov;80(5):674-685. doi: 10.1002/ana.24781.

12.

Identification of genetic modifiers of age-at-onset for familial Parkinson's disease.

Hill-Burns EM, Ross OA, Wissemann WT, Soto-Ortolaza AI, Zareparsi S, Siuda J, Lynch T, Wszolek ZK, Silburn PA, Mellick GD, Ritz B, Scherzer CR, Zabetian CP, Factor SA, Breheny PJ, Payami H.

Hum Mol Genet. 2016 Sep 1;25(17):3849-3862. doi: 10.1093/hmg/ddw206. Epub 2016 Jul 11.

13.

Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients.

Takeda S, Commins C, DeVos SL, Nobuhara CK, Wegmann S, Roe AD, Costantino I, Fan Z, Nicholls SB, Sherman AE, Trisini Lipsanopoulos AT, Scherzer CR, Carlson GA, Pitstick R, Peskind ER, Raskind MA, Li G, Montine TJ, Frosch MP, Hyman BT.

Ann Neurol. 2016 Sep;80(3):355-67. doi: 10.1002/ana.24716. Epub 2016 Aug 3.

14.

A Feed-Forward Circuit of Endogenous PGC-1α and Estrogen Related Receptor α Regulates the Neuronal Electron Transport Chain.

Bakshi R, Mittal S, Liao Z, Scherzer CR.

Parkinsons Dis. 2016;2016:2405176. doi: 10.1155/2016/2405176. Epub 2016 Mar 3.

15.

α-Synuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities.

Lööv C, Scherzer CR, Hyman BT, Breakefield XO, Ingelsson M.

Cell Mol Neurobiol. 2016 Apr;36(3):437-48. doi: 10.1007/s10571-015-0317-0. Epub 2016 Mar 18. Review.

PMID:
26993503
16.

The NINDS Parkinson's disease biomarkers program.

Rosenthal LS, Drake D, Alcalay RN, Babcock D, Bowman FD, Chen-Plotkin A, Dawson TM, Dewey RB Jr, German DC, Huang X, Landin B, McAuliffe M, Petyuk VA, Scherzer CR, Hillaire-Clarke CS, Sieber BA, Sutherland M, Tarn C, West A, Vaillancourt D, Zhang J, Gwinn K; PDBP consortium.

Mov Disord. 2016 Jun;31(6):915-23. doi: 10.1002/mds.26438. Epub 2015 Oct 7.

17.

Aging, the Central Nervous System, and Mobility in Older Adults: Neural Mechanisms of Mobility Impairment.

Sorond FA, Cruz-Almeida Y, Clark DJ, Viswanathan A, Scherzer CR, De Jager P, Csiszar A, Laurienti PJ, Hausdorff JM, Chen WG, Ferrucci L, Rosano C, Studenski SA, Black SE, Lipsitz LA.

J Gerontol A Biol Sci Med Sci. 2015 Dec;70(12):1526-32. doi: 10.1093/gerona/glv130. Epub 2015 Sep 18.

18.

Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease.

Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, Schwarzschild MA, Hayes MT, Wills AM, Shivraj Sohur U, Mejia NI, Selkoe DJ, Oakes D, Shoulson I, Dong X, Marek K, Zheng B, Ivinson A, Hyman BT, Growdon JH, Sudarsky LR, Schlossmacher MG, Ravina B, Scherzer CR.

Brain. 2015 Sep;138(Pt 9):2659-71. doi: 10.1093/brain/awv202. Epub 2015 Jul 28.

19.

High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types.

Doss S, Wandinger KP, Hyman BT, Panzer JA, Synofzik M, Dickerson B, Mollenhauer B, Scherzer CR, Ivinson AJ, Finke C, Schöls L, Müller Vom Hagen J, Trenkwalder C, Jahn H, Höltje M, Biswal BB, Harms L, Ruprecht K, Buchert R, Höglinger GU, Oertel WH, Unger MM, Körtvélyessy P, Bittner D, Priller J, Spruth EJ, Paul F, Meisel A, Lynch DR, Dirnagl U, Endres M, Teegen B, Probst C, Komorowski L, Stöcker W, Dalmau J, Prüss H.

Ann Clin Transl Neurol. 2014 Oct;1(10):822-32. doi: 10.1002/acn3.120. Epub 2014 Oct 18.

20.

Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease.

Santiago JA, Scherzer CR, Potashkin JA.

PLoS One. 2014 Oct 3;9(10):e109042. doi: 10.1371/journal.pone.0109042. eCollection 2014.

21.

Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker study.

Mehanna R, Scherzer CR, Ding H, Locascio JJ.

Neurology. 2014 May 6;82(18):1666; discussion 1666. doi: 10.1212/01.wnl.0000449750.81263.7d. No abstract available.

PMID:
24799519
22.

Motor impulsivity in Parkinson disease: associations with COMT and DRD2 polymorphisms.

Ziegler DA, Ashourian P, Wonderlick JS, Sarokhan AK, Prelec D, Scherzer CR, Corkin S.

Scand J Psychol. 2014 Jun;55(3):278-86. doi: 10.1111/sjop.12113. Epub 2014 Apr 21.

23.

MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration.

Cebrián C, Zucca FA, Mauri P, Steinbeck JA, Studer L, Scherzer CR, Kanter E, Budhu S, Mandelbaum J, Vonsattel JP, Zecca L, Loike JD, Sulzer D.

Nat Commun. 2014 Apr 16;5:3633. doi: 10.1038/ncomms4633.

24.

Metallothioneins as dynamic markers for brain disease in lysosomal disorders.

Cesani M, Cavalca E, Macco R, Leoncini G, Terreni MR, Lorioli L, Furlan R, Comi G, Doglioni C, Zacchetti D, Sessa M, Scherzer CR, Biffi A.

Ann Neurol. 2014 Jan;75(1):127-37. doi: 10.1002/ana.24053.

25.

Specific splice variants are associated with Parkinson's disease.

Santiago JA, Scherzer CR; Harvard Biomarker Study, Potashkin JA.

Mov Disord. 2013 Oct;28(12):1724-7. doi: 10.1002/mds.25635. Epub 2013 Sep 20.

26.

Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study.

Ding H, Dhima K, Lockhart KC, Locascio JJ, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Hayes MT, Sohur US, Wills AM, Mollenhauer B, Flaherty AW, Hung AY, Mejia N, Khurana V, Gomperts SN, Selkoe DJ, Schwarzschild MA, Schlossmacher MG, Hyman BT, Sudarsky LR, Growdon JH, Scherzer CR.

Neurology. 2013 Oct 22;81(17):1531-7. doi: 10.1212/WNL.0b013e3182a95818. Epub 2013 Sep 25.

27.

Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2.

Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER, Mayeux R, Ross OA, Scherzer CR, Simon DK, Tanner C, Vance JM, Wszolek ZK, Zabetian CP, Myers RH, Payami H, Scott WK, Foroud T; PD GWAS Consortium.

Ann Neurol. 2012 Mar;71(3):370-84. doi: 10.1002/ana.22687.

28.

Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis.

van Blitterswijk M, Gulati S, Smoot E, Jaffa M, Maher N, Hyman BT, Ivinson AJ, Scherzer CR, Schoenfeld DA, Cudkowicz ME, Brown RH Jr, Bosco DA.

Amyotroph Lateral Scler. 2011 Nov;12(6):430-8. doi: 10.3109/17482968.2011.585163.

29.

Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse.

Hu Y, Chopra V, Chopra R, Locascio JJ, Liao Z, Ding H, Zheng B, Matson WR, Ferrante RJ, Rosas HD, Hersch SM, Scherzer CR.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17141-6. doi: 10.1073/pnas.1104409108. Epub 2011 Oct 3.

30.

Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study.

Ding H, Sarokhan AK, Roderick SS, Bakshi R, Maher NE, Ashourian P, Kan CG, Chang S, Santarlasci A, Swords KE, Ravina BM, Hayes MT, Sohur US, Wills AM, Flaherty AW, Unni VK, Hung AY, Selkoe DJ, Schwarzschild MA, Schlossmacher MG, Sudarsky LR, Growdon JH, Ivinson AJ, Hyman BT, Scherzer CR.

Mov Disord. 2011 Oct;26(12):2283-6. doi: 10.1002/mds.23934. Epub 2011 Sep 23.

31.

Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures.

Hakimi M, Selvanantham T, Swinton E, Padmore RF, Tong Y, Kabbach G, Venderova K, Girardin SE, Bulman DE, Scherzer CR, LaVoie MJ, Gris D, Park DS, Angel JB, Shen J, Philpott DJ, Schlossmacher MG.

J Neural Transm (Vienna). 2011 May;118(5):795-808. doi: 10.1007/s00702-011-0653-2. Epub 2011 May 7.

32.

PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.

Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grünblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wüllner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet JC, Scherzer CR; Global PD Gene Expression (GPEX) Consortium.

Sci Transl Med. 2010 Oct 6;2(52):52ra73. doi: 10.1126/scitranslmed.3001059.

33.

Lysosomal dysfunction promotes cleavage and neurotoxicity of tau in vivo.

Khurana V, Elson-Schwab I, Fulga TA, Sharp KA, Loewen CA, Mulkearns E, Tyynelä J, Scherzer CR, Feany MB.

PLoS Genet. 2010 Jul 15;6(7):e1001026. doi: 10.1371/journal.pgen.1001026.

34.

Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease.

Lipinski MM, Zheng B, Lu T, Yan Z, Py BF, Ng A, Xavier RJ, Li C, Yankner BA, Scherzer CR, Yuan J.

Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14164-9. doi: 10.1073/pnas.1009485107. Epub 2010 Jul 26.

35.

Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1.

Cho HH, Cahill CM, Vanderburg CR, Scherzer CR, Wang B, Huang X, Rogers JT.

J Biol Chem. 2010 Oct 8;285(41):31217-32. doi: 10.1074/jbc.M110.149161. Epub 2010 Jun 17.

36.

Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease.

Kim J, Amante DJ, Moody JP, Edgerly CK, Bordiuk OL, Smith K, Matson SA, Matson WR, Scherzer CR, Rosas HD, Hersch SM, Ferrante RJ.

Biochim Biophys Acta. 2010 Jul-Aug;1802(7-8):673-81. doi: 10.1016/j.bbadis.2010.05.001. Epub 2010 May 9.

37.

Chipping away at diagnostics for neurodegenerative diseases.

Scherzer CR.

Neurobiol Dis. 2009 Aug;35(2):148-56. doi: 10.1016/j.nbd.2009.02.016. Epub 2009 Mar 10. Review.

38.

GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein.

Scherzer CR, Grass JA, Liao Z, Pepivani I, Zheng B, Eklund AC, Ney PA, Ng J, McGoldrick M, Mollenhauer B, Bresnick EH, Schlossmacher MG.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10907-12. doi: 10.1073/pnas.0802437105. Epub 2008 Jul 31.

39.

RNA biomarkers of Parkinson's disease: developing tools for novel therapies.

Hennecke G, Scherzer CR.

Biomark Med. 2008 Feb;2(1):41-53. doi: 10.2217/17520363.2.1.41.

40.

Molecular markers of early Parkinson's disease based on gene expression in blood.

Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR.

Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):955-60. Epub 2007 Jan 10.

41.

Differences in apolipoprotein E3/3 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease.

Xu PT, Li YJ, Qin XJ, Scherzer CR, Xu H, Schmechel DE, Hulette CM, Ervin J, Gullans SR, Haines J, Pericak-Vance MA, Gilbert JR.

Neurobiol Dis. 2006 Feb;21(2):256-75. Epub 2005 Sep 29.

PMID:
16198584
42.

Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism.

Hauser MA, Li YJ, Xu H, Noureddine MA, Shao YS, Gullans SR, Scherzer CR, Jensen RV, McLaurin AC, Gibson JR, Scott BL, Jewett RM, Stenger JE, Schmechel DE, Hulette CM, Vance JM.

Arch Neurol. 2005 Jun;62(6):917-21.

PMID:
15956162
43.

Loss of apolipoprotein E receptor LR11 in Alzheimer disease.

Scherzer CR, Offe K, Gearing M, Rees HD, Fang G, Heilman CJ, Schaller C, Bujo H, Levey AI, Lah JJ.

Arch Neurol. 2004 Aug;61(8):1200-5. Erratum in: Arch Neurol. 2007 Apr;64(4):557.

PMID:
15313836
44.

Yeast genetics targets lipids in Parkinson's disease.

Scherzer CR, Feany MB.

Trends Genet. 2004 Jul;20(7):273-7. Review. No abstract available. Erratum in: Trends Genet. 2005 Jan;21(1):36.

PMID:
15219388
45.

Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease.

Li YJ, Oliveira SA, Xu P, Martin ER, Stenger JE, Scherzer CR, Hauser MA, Scott WK, Small GW, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Jankovic J, Goetz CG, Mastaglia F, Middleton LT, Roses AD, Saunders AM, Schmechel DE, Gullans SR, Haines JL, Gilbert JR, Vance JM, Pericak-Vance MA, Hulette C, Welsh-Bohmer KA.

Hum Mol Genet. 2003 Dec 15;12(24):3259-67. Epub 2003 Oct 21. Erratum in: Hum Mol Genet. 2004 Mar 1;13(5):573.

PMID:
14570706
46.

Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease.

Scherzer CR, Jensen RV, Gullans SR, Feany MB.

Hum Mol Genet. 2003 Oct 1;12(19):2457-66. Epub 2003 Aug 5.

PMID:
12915459
47.

Paraneoplastic optic neuropathy and cerebellar ataxia with small cell carcinoma of the lung.

Thambisetty MR, Scherzer CR, Yu Z, Lennon VA, Newman NJ.

J Neuroophthalmol. 2001 Sep;21(3):164-7. Review.

PMID:
11725180
48.

Expression of N-methyl-D-aspartate receptor subunit mRNA in the human brain: mesencephalic dopaminergic neurons.

Counihan TJ, Landwehrmeyer GB, Standaert DG, Kosinski CM, Scherzer CR, Daggett LP, Veliçelebi G, Young AB, Penney JB Jr.

J Comp Neurol. 1998 Jan 5;390(1):91-101.

PMID:
9456178
49.

Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: hippocampus and cortex.

Scherzer CR, Landwehrmeyer GB, Kerner JA, Counihan TJ, Kosinski CM, Standaert DG, Daggett LP, Veliçelebi G, Penney JB, Young AB.

J Comp Neurol. 1998 Jan 5;390(1):75-90.

PMID:
9456177
50.

Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: striatum and globus pallidus.

Kosinski CM, Standaert DG, Counihan TJ, Scherzer CR, Kerner JA, Daggett LP, Veliçelebi G, Penney JB, Young AB, Landwehrmeyer GB.

J Comp Neurol. 1998 Jan 5;390(1):63-74.

PMID:
9456176

Supplemental Content

Loading ...
Support Center